- Bone Marrow Transfusion/ Stem Cell Therapy
- Blood Transfusion
- Drug Therapy
- Others
Aplastic Anemia Market size was valued at USD 6,440.9 million in 2022 and is poised to grow at a CAGR of 5.2% over 2023-2029. Aplastic Anemia is a severe hematologic condition in which the body fails to make blood cells in sufficient numbers, causing a deficiency of all blood cell types, and is associated with cancer and various cancer syndromes. Based on the treatment type, drug therapy is anticipated to dominate the market share over the forecast period. According to a research report, aplastic anemia has an incidence of approximately 2 to 7 cases per million individuals per annum. The rise in the frequency of blood disorders globally and growing awareness will act as the growth drivers for the market, however, the high cost of treatment would be the lagging factor for the market. Growing demand for reliable and short treatment options, and increasing government support for research and development will be the opportunities for aplastic anemia market expansion.
Aplastic Anemia Market Key Developments:
- In June 2021, Heartseed and Novo Nordisk entered into a global collaboration and licensing agreement for HS-001, a stem cell-based heart failure therapy, to develop and co-commercialize the product.
- In August 2021, GSK received FDA approval for Jemperli (Dostarlimab), for the treatment of aplastic anemia.
Aplastic Anemia Market Summary
Study Period
2023-29
Base Year
2022
CAGR
5.2%
Largest Market
North America
Fastest Growing Market
Asia Pacific
Aplastic Anemia Market Dynamics
The Aplastic Anemia and MDS International Foundation, National Organization for Rare Disorders and Cancer index are spreading awareness about aplastic anemia, for instance in Feb 2019, the Aplastic Anemia Trust spring awareness Campaign was launched. Furthermore, since May 2021, a clinical trial has been going on to assess the long-term efficacy and safety of Romiplostim in patients with aplastic anemia. Thus, the increased awareness, research and development and rapidly developing technology will lead to market growth within the forecast period.
North-America Got Significant Share of
Aplastic Anemia Market Regional Analysis
The aplastic Anemia market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. According to the Centers for Disease Control and Prevention, in the USA, hemophilia A affects 1 in 5,000 male newborns, and about 400 babies are born with hemophilia A each year, and an estimated incidence of hemophilia is 1 per 12,000 annually, moreover, in 2021, the USA experienced 1,86,400 new cases of leukemia, lymphoma, and myeloma. Based on the Leukemia & Lymphoma Society, approximately one person is diagnosed with leukemia, lymphoma, or myeloma every three minutes, and blood cancer accounted for about 10% of cancer diagnoses in Canada in 2019. The North America Aplastic Anemia market is expected to dominate the market over the forecast period, owing to well-developed technology, increasing patients with blood disorders, increasing prevalence of cancer, high healthcare spending, and government support for R&D activities. Asia Pacific has become the fastest-growing aplastic anemia market, due to the developing healthcare technology, and huge patient population.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The aplastic anemia market report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments and startup’s details that are actively working in the market
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
- The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Aplastic Anemia Market Segmentation
By Treatment
By Disease Type
- Acquired Aplastic Anemia
- Inherited Aplastic Anemia
By Diagnosis
- Bone Marrow Biopsy
- CT Scan
By End User
- Hospitals
- Specialty Clinics
- Homecare
- Others
Frequently Asked Questions
The Aplastic Anemia market was valued at USD 6,440.9 million in 2022 and is expected to grow at a 5.2% CAGR over the forecast period 2023 – 2029.
Growing demand for reliable and short treatment options, and increasing government support for research and development will be the opportunities for aplastic anemia market expansion are the key opportunities for Aplastic Anemia market.
The rise in the frequency of blood disorders globally and growing awareness are the growth drivers in the Aplastic Anemia market.
Pfizer Inc., Bayer Ag, Novartis AG, Ligand Pharmaceuticals Incorporated, Genzyme Corporation, Mylan N.V., Biogen, Otsuka Pharmaceutical Co. Ltd., Regen BioPharma Inc., and BioLineRx are a few companies operating in the Aplastic Anemia market.
- Pfizer Inc
- Bayer Ag
- Novartis AG
- Ligand Pharmaceuticals Incorporated
- Genzyme Corporation
- Mylan N.V.
- Biogen
- Otsuka Pharmaceutical Co. Ltd.
- Regen BioPharma Inc.
- BioLineRx